MedTrace Logo

Prevalence of Wildtype Amyloid After TAVR

NCT03825406 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-03-22

No results posted yet for this study

Summary

Those with abnormal vital signs after TAVR need to be willing to obtain a bone scan to evaluate for wildtype amyloidosis. Positive bone scan findings will require evaluation for primary amyloidosis with blood and urine monoclonal immunoglobulin testing. Primary amyloidosis is a different type of disease which requires different treatment.

Conditions

  • Amyloidosis

Sponsors & Collaborators

  • North Florida Foundation for Research and Education

    lead OTHER

Principal Investigators

  • Anthony Bavry, MD · ACC AHA

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2019-03-20
Completion
2019-03-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03825406 on ClinicalTrials.gov